Short answer
LB PHARMACEUTICALS INC (LBRX) filed its Q2 2026 10-Q quarterly report on Aug 11, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$52M
- −170.8% QoQ
- EPS (diluted)
- −$1.75
- −161.2% QoQ
Source: XBRL data from the LB PHARMACEUTICALS INC (LBRX) Q2 2026 10-Q on SEC EDGAR. USD.
LB PHARMACEUTICALS INC Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly triggered risk: LB-102 development expansion into adjunctive MDD and additional neuropsychiatric indications increasing anticipated expenses
- Clinical risk: Phase 3 schizophrenia endpoint relies on subjective PANSS assessments, increasing variability and placebo-effect uncertainty
- Regulatory risk: FDA may require additional preclinical studies or protocol amendments before future trial initiation
- Financial risk: $327.8 million cash, equivalents, and marketable securities funding operations for at least 12 months
- Royalty risk: LB-102 obligations reach 2.75% of worldwide net sales through 2035 and 3.25% thereafter in perpetuity
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other LB PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.